Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with FOLFOX in Stage II/III Rectal Cancer
NCT00303628Phase 3Terminated
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- May 2006
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of bevacizumab in rectal cancer, sponsored by ECOG-ACRIN Cancer Research Group. Started May 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00303628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303628.